Physician profile
Brian D Ardel
NPI 1326081530
$15,680.88
in general payments reported to CMS, 2019-2025
53 companies · $1,496 in 2025
The $1,496 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,231 · 2020: $2,195 · 2021: $2,028 · 2022: $1,805 · 2023: $1,819 · 2024: $3,107 · 2025: $1,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,040 · Travel and Lodging: $370 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,040.37 |
| Travel and Lodging | $369.87 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,931.82 | 2019-2024 | Xarelto |
| Amgen INC. | $1,504.82 | 2019-2024 | Repatha, Otezla, Evenity |
| Boston Scientific Corporation | $1,321.92 | 2019-2025 | Watchman Access System, Watchman Flx, Farapulse |
| Astrazeneca Pharmaceuticals LP | $1,267.55 | 2019-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $991.61 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $938.27 | 2020-2025 | Mitraclip, Jot Dx, Infinity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $698.18 | 2019-2024 | Jardiance |
| Abbvie INC. | $692.58 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $627.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $467.08 | 2020-2024 | Nexletol, Nexlizet |
| Glaxosmithkline, LLC. | $459.45 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $451.82 | 2019-2023 | |
| Mylan Specialty L.P. | $283.67 | 2019-2023 | Yupelri, Yupelri |
| Acadia Pharmaceuticals INC | $250.00 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $245.21 | 2020-2023 | Verquvo |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ardel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.